Compare Eli Lilly And Co (LLY) vs PayPal Holdings, Inc. (PYPL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Eli Lilly And Co vs PayPal Holdings, Inc. — how do they compare? Eli Lilly And Co trades at $1,179.27 (market cap $1.04T), while PayPal Holdings, Inc. trades at $55.53 (market cap $47.07B). The key difference: Eli Lilly And Co is far larger — about 22.1× PayPal Holdings, Inc.'s market cap, and PayPal Holdings, Inc. pays the higher dividend (1.02%). Which is the better fit depends on your goals — on Pluang, investors hold Eli Lilly And Co for 93 Days and PayPal Holdings, Inc. for 106 Days on average.
| LLY | PYPL | |
|---|---|---|
Market Cap | $1.04T | $47.07B |
Volume | 3,064,878 | 13,860,099 |
Sector | Health | Financials |
52-Week High | $1.28K | $75.75 |
52-Week Low | $799.57 | $39.08 |
Typical Hold Time | 93 Days | 106 Days |
Enterprise Value | $1.09T | $49.21B |
Dividend Yield | 0.59% | 1.02% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Eli Lilly (LLY) trades at $1,169.93, down 1.58% on the day, but maintains strong bullish momentum with consistent earnings beats and robust revenue growth. The company demonstrates exceptional profitability with 83.4% gross margins and 33.53% net income margins, supported by dominant positioning in weight-loss and diabetes treatments. Recent clinical trial successes for next-generation drugs and expanded FDA approvals reinforce growth prospects.
LLY presents compelling growth potential with analyst consensus target of $1,350 representing 15% upside, though elevated valuations (P/E 39.26) and increasing competition in obesity drugs pose risks. Strong institutional support (73% buy ratings) and positive pipeline developments support continued momentum, but investors should monitor execution risks and market saturation concerns.
PayPal (PYPL) trades at $55.02, up 0.13% on the day, with a bullish technical signal supported by moving averages. The stock shows strong fundamentals with a P/E of 10.4, net income margin of 14.36%, and recent earnings beats. Recent news highlights a Meta partnership for AI-powered checkout, potentially driving growth. Cash flow remains healthy with $1.53B net cash flow in 2025.
PYPL presents a value opportunity with attractive valuation multiples and solid profitability, though competition in digital payments and slowing branded checkout growth pose risks. Analyst consensus is mixed with a $56.41 price target, suggesting modest upside from current levels. The Meta partnership and cost-cutting initiatives under new CEO Enrique Lores provide catalysts for potential re-rating.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Eli Lilly And Co
Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer
Read more on LLY →About PayPal Holdings, Inc.
PayPal Holdings, Inc. operates as a technology platform company that enables digital and mobile payments on behalf of consumers and merchants. The Company offers online payment solutions. PayPal Holdings serves customers worldwide.
Read more on PYPL →
